Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Shanghai Zhongshan Hospital
With
Shanghai Shen Kang Hospital Development Center
Tongji Hospital
RenJi Hospital
Shanghai 10th People's Hospital
Shanghai General Hospital, China
This study aims to investigate the potential prognostic benefits of evolocumab in patients with MVD after AMI at 2-year follow-up. The primary endpoint is MACE, defined as a composite of cardiac death, myocardial infarction, stroke, angina-driven coronary revascularization, and rehospitalization for heart failure. This is a multicentre, cohort-based TTE study and the target RCT is the FOURIER trial.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age ≥18 years old;
Acute myocardial infarction diagnosed at hospital admission;
Multivessel coronary artery disease diagnosed at primary invasive coronary angiography;
Culprit vessel successfully revascularized;
At lease 1 non-culprit vessel with ≥50% stenosis and deferred at the opinion of the operator, and no staged revascularization within 6 months.
You may not be if
Cardiac shock, hemodynamically unstable, or severe heart failure (Killip IV)
Any cardiac surgery within 6 weeks prior to screening;
Moderate to severe renal dysfunction, defined as an estimated glomerular filtration rate (eGFR) less than 30 mL/min/1.73m\^2 at screening;
Contraindication or allergy to iodinated contrast agent;
Malignancy except non-melanoma skin cancers, cervical, or breast ductal carcinoma in situ within the last 5 years;
Female subject is pregnant or breastfeeding or planning to become pregnant or breastfeed in short term.